{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:17:01Z","timestamp":1777969021662,"version":"3.51.4"},"reference-count":19,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15527","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:04:12Z","timestamp":1773320652000},"page":"1-10","source":"Crossref","is-referenced-by-count":1,"title":["Effect of apalutamide dosage on the incidence of cutaneous adverse events and prostate\u2011specific antigen reduction in patients with prostate cancer"],"prefix":"10.3892","volume":"31","author":[{"given":"Takuya","family":"Matsuyam","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Go","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Murase","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiseki","family":"Usami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503\u20118502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"key20260505102750_b1-ol-31-5-15527","first-page":"17","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20260505102750_b2-ol-31-5-15527","article-title":"Erleada (apalutamide) package insert, 2024","author":"Janssen Pharmaceutical K.K."},{"key":"key20260505102750_b3-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260505102750_b4-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260505102750_b5-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: An integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol"},{"key":"key20260505102750_b6-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.prnil.2020.05.002","article-title":"Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase-3 study","volume":"8","author":"Uemura","year":"2020","journal-title":"Prostate Int"},{"key":"key20260505102750_b7-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/iju.14860","article-title":"Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study","volume":"29","author":"Sasaki","year":"2022","journal-title":"Int J Urol"},{"key":"key20260505102750_b8-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.21873\/anticanres.15682","article-title":"Low body weight as a risk factor for apalutamide-related cutaneous adverse events","volume":"42","author":"Katsuta","year":"2022","journal-title":"Anticancer Res"},{"key":"key20260505102750_b9-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10147-022-02183-z","article-title":"Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: A multi-institutional study in the Chu-shikoku Japan Urological Consortium","volume":"27","author":"Tohi","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"key20260505102750_b10-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/pros.24453","article-title":"Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study","volume":"83","author":"Oishi","year":"2023","journal-title":"Prostate"},{"key":"key20260505102750_b11-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","article-title":"Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN","volume":"81","author":"Saad","year":"2022","journal-title":"Eur Urol"},{"key":"key20260505102750_b12-ol-31-5-15527","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S","author":"National Cancer Institute","year":"2017"},{"key":"key20260505102750_b13-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"key20260505102750_b14-ol-31-5-15527","article-title":"Clinical Practice Guidelines for Prostate Cancer 2023","author":"Japanese Urological","year":"2023"},{"key":"key20260505102750_b15-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00345-024-04880-y","article-title":"Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer","volume":"42","author":"Yang","year":"2024","journal-title":"World J Urol"},{"key":"key20260505102750_b16-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.prnil.2024.10.003","article-title":"Skin rash in metastatic hormone sensitive prostate cancer patients treated with apalutamide: A retrospective multicenter study in Korea","volume":"13","author":"Kim","year":"2025","journal-title":"Prostate Int"},{"key":"key20260505102750_b17-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-022-04427-1","article-title":"Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: Results from the phase 3 TITAN study","volume":"89","author":"T'jollyn","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20260505102750_b18-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jjco\/hyad143","article-title":"Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: A multi-institutional study in the Chu-shikoku Japan Urological Consortium","volume":"54","author":"Tohi","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"key20260505102750_b19-ol-31-5-15527","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/jjco\/hyaf082","article-title":"Skin rash induced by apalutamide correlated with age and relative dose intensity adjusted by body surface area in Japanese patients with prostate cancer","volume":"55","author":"Akagi","year":"2025","journal-title":"Jpn J Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:27:58Z","timestamp":1777966078000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15527","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}